Clinical trial · Interventional
Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients
Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is: * to compare the effectiveness between the new strategy of treatment (given cis-platinum plus gemcitabine-neoadjuvant chemotherapy followed by surgery),and standard treatment (given cis-platinum/carboplatin during radiation-concurrent chemoradiation)in specific group of cervical cancer patients (stage Ib2-early IIb) * to evaluate quality of life in both group of patients(standard treatment vs.experimental group)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant chemotherapy followed by surgery | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cisplatin plus gemcitabine
- description
- Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
- interventionNames
- Other: Neoadjuvant chemotherapy followed by surgery
Primary outcomes (1)
- measure
- Overall survival comparison between experimental treatment group and standard treatment group
- timeFrame
- 9 Years
Secondary outcomes (1)
- measure
- Comparing disease free survival between experimental treatment group and standard treatment group
- timeFrame
- 9 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Cervical cancer patients with FIGO stage Ib2-early IIb * Pathological proven squamous cell carcinoma or adenocarcinoma or adenosquamous cell carcinoma * ECOG performance status 0-1 * No previous treatment for cervical cancer * Acceptable hematological,renal,liver function Exclusion Criteria: * Previous history of cancer * Underlying disease not fit for surgery * Psychological problem * Obvious pelvic/para-aortic node involvement * Pregnancy * HIV positive * History of bowel obstruction
References
Publications (1)
- BACKGROUNDTermrungruanglert W, Tresukosol D, Vasuratna A, Sittisomwong T, Lertkhachonsuk R, Sirisabya N. Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. Gynecol Oncol. 2005 May;97(2):576-81. doi: 10.1016/j.ygyno.2005.01.048. PMID 15863162